GenSpera, Inc. (OTCBB:GNSZ) announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas. CTRC joins the University of Wisconsin Carbone Cancer Center, in Madison, Wisconsin, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, in Baltimore, Maryland, as the third center to participate in the Phase I safety study evaluating G-202 in patients whose cancers have progressed after treatment with other chemotherapies.
“We have carefully selected our clinical hospitals for both their expertise and to reach a cross-section of patients, and are pleased to bring this third center of excellence into our trial.”
"I am glad to have the opportunity to offer my patients another novel therapeutic agent to treat their cancer," said Devalingam Mahalingam, M.D. Ph.D., principal investigator of the study at the CTRC. "G-202 has shown much promise in pre-clinical testing, so I am hopeful it will show good clinical activity in my patients."
"We are delighted that CTRC is now treating patients," commented Craig Dionne, Ph.D., GenSpera CEO and President. "We have carefully selected our clinical hospitals for both their expertise and to reach a cross-section of patients, and are pleased to bring this third center of excellence into our trial."
New findings could make off-the-shelf CAR T cell therapy a reality